Kymera Therapeutics (KYMR) Projected to Release Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR) is expected to issue its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Kymera Therapeutics to post earnings of ($1.27) per share and revenue of $3.10 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The business had revenue of $65.00 million for the quarter, compared to analysts’ expectations of $32.78 million. During the same period in the prior year, the firm earned ($0.95) earnings per share. Kymera Therapeutics’s revenue was up 465.2% compared to the same quarter last year. On average, analysts expect Kymera Therapeutics to post ($3.85) EPS for the current fiscal year and ($5.09) EPS for the next fiscal year.

Kymera Therapeutics Price Performance

KYMR stock opened at $114.84 on Tuesday. Kymera Therapeutics has a fifty-two week low of $55.66 and a fifty-two week high of $130.05. The stock has a market capitalization of $9.55 billion, a PE ratio of -35.44 and a beta of 1.98. The company has a 50 day moving average price of $114.98 and a 200 day moving average price of $95.40.

Analysts Set New Price Targets

Several brokerages have recently commented on KYMR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, October 15th. B. Riley Financial lifted their target price on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Deutsche Bank Aktiengesellschaft started coverage on shares of Kymera Therapeutics in a research report on Thursday, July 30th. They set a “hold” rating and a $120.00 target price for the company. Raymond James Financial started coverage on Kymera Therapeutics in a research note on Thursday, October 8th. They set an “outperform” rating and a $140.00 price objective for the company. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $135.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $134.68.

Insider Activity at Kymera Therapeutics

In other news, insider Brian Adams sold 6,371 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the completion of the transaction, the insider owned 50,254 shares in the company, valued at $5,871,174.82. This represents a 11.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the completion of the transaction, the chief executive officer owned 666,568 shares of the company’s stock, valued at $75,855,438.40. This trade represents a 4.31% decrease in their position. The SEC filing for this sale provides additional information. 15.98% of the stock is currently owned by insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.